Newron Pharmaceuticals SpA Asset Resilience Ratio
Newron Pharmaceuticals SpA asset resilience ratio. Newron Pharmaceuticals SpA (NWRN) has an Asset Resilience Ratio of 41.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Newron Pharmaceuticals SpA defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Newron Pharmaceuticals SpA (2009–2025)
Asset resilience ratio of Newron Pharmaceuticals SpA from 2009 to 2025. This chart shows how Newron Pharmaceuticals SpA's Asset Resilience Ratio has changed over time. Read total liabilities of Newron Pharmaceuticals SpA for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Newron Pharmaceuticals SpA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Newron Pharmaceuticals SpA (NWRN) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF16.68 Million | 41.67% |
| Total Liquid Assets | CHF16.68 Million | 41.67% |
Asset Resilience Insights
- Very High Liquidity: Newron Pharmaceuticals SpA maintains exceptional liquid asset reserves at 41.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Newron Pharmaceuticals SpA Industry Peers by Asset Resilience Ratio
Compare Newron Pharmaceuticals SpA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Newron Pharmaceuticals SpA Asset Resilience Ratio by Year (2009–2025)
Newron Pharmaceuticals SpA asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for Newron Pharmaceuticals SpA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.67% | CHF16.68 Million ≈ $21.08 Million |
CHF40.02 Million ≈ $50.60 Million |
+37.14pp |
| 2024-12-31 | 4.53% | CHF2.89 Million ≈ $3.66 Million |
CHF63.91 Million ≈ $80.80 Million |
-19.68pp |
| 2023-12-31 | 24.21% | CHF6.26 Million ≈ $7.92 Million |
CHF25.87 Million ≈ $32.70 Million |
-0.93pp |
| 2022-12-31 | 25.14% | CHF9.35 Million ≈ $11.82 Million |
CHF37.20 Million ≈ $47.02 Million |
+6.17pp |
| 2021-12-31 | 18.97% | CHF9.57 Million ≈ $12.11 Million |
CHF50.49 Million ≈ $63.83 Million |
-16.26pp |
| 2020-12-31 | 35.23% | CHF18.04 Million ≈ $22.80 Million |
CHF51.20 Million ≈ $64.73 Million |
+6.85pp |
| 2019-12-31 | 28.38% | CHF17.11 Million ≈ $21.63 Million |
CHF60.29 Million ≈ $76.22 Million |
+1.33pp |
| 2018-12-31 | 27.05% | CHF16.23 Million ≈ $20.52 Million |
CHF60.00 Million ≈ $75.85 Million |
+0.43pp |
| 2017-12-31 | 26.62% | CHF19.44 Million ≈ $24.58 Million |
CHF73.02 Million ≈ $92.32 Million |
+20.40pp |
| 2016-12-31 | 6.22% | CHF3.52 Million ≈ $4.45 Million |
CHF56.59 Million ≈ $71.55 Million |
-4.87pp |
| 2015-12-31 | 11.09% | CHF4.92 Million ≈ $6.22 Million |
CHF44.38 Million ≈ $56.11 Million |
-7.65pp |
| 2014-12-31 | 18.74% | CHF6.95 Million ≈ $8.78 Million |
CHF37.07 Million ≈ $46.87 Million |
+1.48pp |
| 2013-12-31 | 17.26% | CHF5.46 Million ≈ $6.90 Million |
CHF31.62 Million ≈ $39.97 Million |
+9.10pp |
| 2012-12-31 | 8.16% | CHF3.64 Million ≈ $4.60 Million |
CHF44.65 Million ≈ $56.45 Million |
+4.30pp |
| 2009-12-31 | 3.85% | CHF1.60 Million ≈ $2.03 Million |
CHF41.68 Million ≈ $52.69 Million |
-- |
About Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more